A skin protection mount protects the skin surface of a subject from damage that can result from repeated attachment and detachment of transcutaneous sensors connected to the skin of a subject with adhesive. The skin protection mount preferably has a thickness of five mils or less, to provide increased flexibility and increase subject comfort. Preferably, the skin protection mount has adhesive on the side attached to the subject, and lacks adhesive on the opposite side in order to facilitate attachment to and detachment from a skin protection mount of a transcutaneous sensor having an adhesive zing with an adhesion surface. In a preferred embodiment, the mounting surface of the skin protection mount has a surface area larger than the adhesion surface to protect the subject's skin from the adhesion surface. The adhesive force between the skin protection mount and the patient is greater than the adhesive force between the skin protection mount and the adhesion surface of the adhesive ring.

Patent
   6295463
Priority
Jan 04 2000
Filed
Jan 04 2000
Issued
Sep 25 2001
Expiry
Jan 04 2020
Assg.orig
Entity
Large
164
7
all paid
1. An apparatus for protecting the skin of a subject comprising:
an adhesive ring having a ring passage therethrough and an adhesion surface; and
a flexible skin protection mount permanently attached to a patient, having an attachment surface at the interface between the flexible skin protection mount and the skin of the patient bearing an adhesive, an opposed mounting surface onto which the adhesion surface of the adhesive ring adheres, and a mount passage extending therethrough and encompassing an area smaller than the area encompassed by the ring passage, said mounting surface having a larger surface area than the adhesion surface of the adhesive ring.
10. An apparatus for protecting the skin of a subject comprising:
an adhesive ring having a ring passage therethrough and an adhesion surface;
a flexible skin protection mount permanently attached to a patient, having an attachment surface at the interface between the flexible skin protection mount and the skin of the patient bearing an adhesive, an opposed mounting surface onto which the adhesion surface of the adhesive ring adheres, and a mount passage extending therethrough and encompassing an area smaller than the area encompassed by the ring passage, said mounting surface having a surface area and shape substantially the same as the surface area and shape of the adhesion surface of the adhesive ring; and
wherein the adhesive force between said attachment surface and the patient is greater than the adhesive force between said mounting surface and the adhesion surface of the adhesive ring.
24. A method of protecting the skin of a patient from a transcutaneous sensor having an electrode comprising the steps of:
adhering the transcutaneous sensor to an adhesive ring with an adhesive, the adhesive ring having a ring passage therethrough for passage of the electrode;
adhering to the skin a non-removable, flexible skin protection mount with an adhesive, the non-removable, flexible skin protection mount having a mount passage therethrough for passage of the electrode; and
adhering the transcutaneous sensor and adhesive ring to the non-removable, flexible skin protection mount with an adhesive, wherein the adhesive force between the non-removable, flexible skin protection mount and the patient's skin is greater than the adhesive force between the non-removable, flexible skin protection mount and the adhesive ring and wherein the electrode from the transcutaneous sensor passes through the ring passage and the mount passage to substantially contact the patient's skin.
18. A skin protection mount for use with a transcutaneous sensor comprising:
a transcutaneous sensor having an electrode;
an adhesive ring having a ring passage between first and second sides thereof, the transcutaneous sensor being attached to the first side of the adhesive ring with an adhesive, wherein the electrode of the transcutaneous sensor passes through the ring passage;
a skin protection mount having a mount passage extending between an attachment surface for permanently attaching the skin protection mount to the skin of the patient using an adhesive and an opposing mounting surface for releasably engaging with the second side of the adhesive ring using an adhesive; and
wherein the transcutaneous sensor and adhesive ring are releasably engagable with the opposing mounting surface of the skin protection mount such that the electrode of the transcutaneous sensor passes through the mount passage to substantially contact the patient's skin when the transcutaneous sensor and adhesive ring are engaged with the surface protection mount and such that the adhesive force between the attachment surface of the skin protection mount and the skin of the patient is greater than the adhesive force between the opposing mounting surface of the skin protection mount and the second side of the adhesive ring.
2. The apparatus of claim 1, wherein the adhesive force between said attachment surface and the patient is greater than the adhesive force between said mounting surface and the adhesion surface of the adhesive ring.
3. The apparatus of claim 1, wherein said adhesion surface bears adhesive and said mounting surface is substantially free of adhesive.
4. The apparatus of claim 1, wherein said skin protection mount is less than or substantially equal to five mils thick.
5. The apparatus of claim 1, wherein said skin protection mount is composed of polyethylene.
6. The apparatus of claim 1, wherein said adhesive on said attachment surface is acrylic co-polymer.
7. The apparatus of claim 1, wherein said adhesive on said attachment surface is acrylate.
8. The apparatus of claim 1, further comprising a ring cap secured to the adhesive ring when the adhesive ring is not attached to said mounting surface.
9. The apparatus of claim 1, wherein the adhesive ring is part of a unitary sensor assembly.
11. The apparatus of claim 10, wherein said adhesion surface bears adhesive and said mounting surface is substantially free of adhesive.
12. The apparatus of claim 10, wherein said skin protection mount is less than or substantially equal to five mils thick.
13. The apparatus of claim 10, wherein said skin protection mount is composed of polyethylene.
14. The apparatus of claim 10, wherein said adhesive on said attachment surface is acrylic co-polymer.
15. The apparatus of claim 10, wherein said adhesive on said attachment surface is acrylate.
16. The apparatus of claim 10, further comprising a ring cap secured to the adhesive ring when the adhesive ring is not attached to said mounting surface.
17. The apparatus of claim 10, wherein the adhesive ring is part of a unitary sensor assembly.
19. The apparatus of claim 18, wherein the adhesive ring has a thickness between 1 and 3 mils.
20. The apparatus of claim 19, wherein the skin protection mount has a thickness of five mils or less.
21. The apparatus of claim 18, wherein the mount passage is smaller than the ring passage.
22. The apparatus of claim 18, wherein the surface area of the interface between the skin protection mount and the patient's skin is greater than the surface area of the interface between the adhesive ring and the skin protection mount.
23. The apparatus of claim 18, wherein a stronger adhesive is used between the interface between the skin protection mount and the patient's skin than the adhesive used between the interface between the adhesive ring and the skin protection mount.

The field of invention is mounting transcutaneous sensors to a subject, and more specifically a skin protection mount for attachment to a subject between the subject's skin and a transcutaneous sensor.

Transcutaneous sensors are well-known noninvasive devices for measuring certain processes and properties of a subject. For example, a transcutaneous blood gas sensor allows for noninvasive measurement of the partial pressure of oxygen and carbon dioxide in the bloodstream by measuring the oxygen and carbon dioxide that permeate through the skin and into the sensor. A typical transcutaneous sensor has an electrode substantially resting against the skin that takes part in detecting the matters of interest. Generally, a layer of gel or solution is placed on the skin so that contact between the skin and the electrode takes places via that gel or solution. Transcutaneous sensors are usually attached to the skin with an adhesive ring having a sticky coating on both sides. One side of the adhesive ring is attached to the sensor, and the other half is attached to the skin. A hole in the center of the adhesive ring allows the electrode in the transcutaneous sensor to substantially touch the skin of the subject.

Commonly, the adhesive ring is attached to the sensor, and is removed from the skin with the sensor. Removal of the sensor occurs on a frequent basis. Transcutaneous blood gas sensors use a heated electrode, which can only be used in one place for a limited time before patient discomfort or an actual bum occurs; premature babies are particularly susceptible to such problems. Typically, such sensors must be removed from a given location on the subject after 2 hours of use in order to prevent discomfort or burns. A transcutaneous sensor may also be removed for placement on a different area of the patient, for replacement, or to allow patient movement without restriction by the sensor. As will be familiar to anyone who has removed an adhesive bandage, removing an adhesive item from the skin can be very irritating to quite painful, and can arouse significant apprehension, particularly in children. More importantly, when the adhesive ring is removed, it can pull up some of the skin layer with it. This can cause a problem with subjects having immature skin or skin disorders. For example, premature infants do not generally have a fully mature cutaneous layer. Yet, transcutaneous sensors must often be placed on premature infants to monitor and ensure their health. Thus, removal of those sensors can cause both pain and skin damage to premature infants.

To reduce skin damage, it is known to place plastic mounting rings on the subject's body at locations where transcutaneous sensing is desired. These plastic mounting rings are made of hard plastic and are thick enough, typically at least a millimeter, to be rigid. Such plastic mounting rings are placed on the subject once, and remain on the subject even when there is no sensor attached to them. A sensor can thus be attached to a plastic mounting ring, then detached from that plastic mounting ring and moved to a different plastic mounting ring, without the detaching process causing pain or skin damage. However, the plastic mounting rings are rigid, and can thus cause discomfort to the subject as he or she moves. They may be particularly uncomfortable for premature infants, for whom the plastic mounting rings are very large--typically about 0.75 inches in diameter--in comparison to their body size.

An object of the present invention is to provide a mounting surface for a transcutaneous sensor that protects a subject's skin from damage. Another object of the present invention is to provide a mounting surface for a transcutaneous sensor that is more comfortable for the subject than existing mounting surfaces. In one aspect of a preferred embodiment, a skin protection mount has a thickness of five mils or less, to provide greater flexibility and increase subject comfort. In another aspect of a preferred embodiment, the skin protection mount has adhesive on the side attached to the subject, and substantially lacks adhesive on the opposite side to facilitate attachment to and detachment from the skin protection mount of a transcutaneous sensor having an adhesive ring with an adhesion surface. In a further aspect of a preferred embodiment, the adhesive force between the skin protection mount and the patient is greater than the adhesive force between the skin protection mount and the adhesion surface of the adhesive ring. In another aspect of a preferred embodiment, the mounting surface of the skin protection mount has a surface area larger than the adhesion surface to protect the subject's skin from the adhesion surface. Other and further objects and advantages will appear hereinafter.

FIG. 1 is an exploded view of a preferred embodiment of a skin protection mount as used in conjunction with a sensor and a subject.

FIG. 2 is a bottom view of a preferred embodiment of an adhesive ring.

FIG. 3 is a top view of a preferred embodiment of a skin protection mount.

FIG. 4 is a top view of a preferred embodiment of a skin protection mount as used in conjunction with a sensor and a subject.

Referring to FIG. 1, a skin protection mount 2, an adhesive ring 4, and a transcutaneous sensor 6 can be seen. The transcutaneous sensor 6 may be a blood gas sensor or other type of sensor for detecting physiological information from a subject. Such information is typically transmitted to a computer or other monitoring device over a wire 8 or any other known form of communications transmission. Transcutaneous sensors 6 are well known in the art, and are readily available from several manufacturers; the present invention is not limited to use with any particular brand or model of transcutaneous sensor. One such device is the SensorMedics Microgram 7650 Transcutaneous Monitor.

FIG. 1 shows the adhesive ring 4 as part of an exploded view. In a preferred embodiment, the adhesive ring 4 is substantially covered with adhesive on both sides. When the transcutaneous sensor 6 is in use, the sensor is attached to the adhesive ring 4 via that adhesive. Referring to FIG. 2, a bottom view of the adhesive ring 4 can be seen. A ring passage 10 extends through the adhesive ring 4. The adhesive ring 4 has an adhesion surface 5, which in the prior art is attached directly to the subject's skin 18. Referring back to FIG. 1, the skin protection mount 2 has an attachment surface 12, and a mounting surface 14 on the opposite side from the attachment surface 12. FIG. 3 shows a top view of the skin protection mount 2. A mount passage 16 extends through the skin protection mount 2.

In a preferred embodiment, the skin protection mount 2 is composed of polyethylene. However, the skin protection mount 2 can be made from other flexible, non-toxic materials capable of withstanding the stress of repetitive attachment and detachment of the adhesive ring 4 without substantially failure by tearing or otherwise.

In a preferred embodiment, the attachment surface 12 of the skin protection mount 2 is covered in whole or in part with an adhesive substance, in any manner or pattern that provides for secure attachment between the skin protection mount 2 and the subject's skin 18. Such adhesive substance maybe any nontoxic adhesive that is compatible with the subject's skin 18; the specific type of adhesive used is unimportant. In a preferred embodiment, the attachment surface 12 is substantially coated with acrylic co-polymer adhesive. In another preferred embodiment, the attachment surface 12 is substantially coated with acrylate adhesive. The attachment surface 12 of the skin protection mount 2 is then placed onto the subject's skin 18.

When placed on a patient, the skin protection mount 2 is meant to be permanently or non-removably attached to the patient. This means that the mount will remain attached to the skin when the sensor is detached from the patient. Of course, the mount can be removed from the patient whenever medical necessity, patient comfort or other need arises. Thus, in the preferred embodiment the skin protection mount 2 remains permanently or non-removably attached to the patient even when the sensor 6 is removed from or repositioned on the patient. Preferably, removal of the skin protection mount 2 only occurs primarily if the mount is somehow damaged, its adhesion to the skin becomes weakened, cleaning is needed, medical necessity requires removal, or further measurements are not required from the patient.

The mounting surface 14 is adapted to connect to the adhesive ring 4. The adhesion surface 5 of the adhesive ring 4 bears an adhesive substance with which the adhesive ring 4 is attached to the mounting surface. Preferably, that adhesive substance is acrylic co-polymer or acrylate. However, other adhesive substances capable of providing attachment between the adhesive ring 4 and the mounting surface 14 may be used if desired.

The adhesive force between the attachment surface 12 and the subject's skin 18 is greater than the adhesive force between the mounting surface 14 and the adhesive ring 4. The adhesive force is a function of the adhesive strength and the surface area over which it is applied. When it is desired to remove the sensor 6 and the adhesive ring 4 from the skin protection mount 2, a force slightly greater than the adhesive force between the adhesive ring 4 and the mounting surface 14 is applied to the adhesive ring 4. By providing for an adhesive force between the adhesive ring 4 and the mounting surface 14 that is less than the adhesive force between the attachment surface 12 and the subject's skin 18, the adhesive ring 4 may be easily removed from the skin protection mount 2, without inadvertently remaining attached to the skin protection mount 2 and detaching the skin protection mount 2 from the subject's skin 18 instead.

In a preferred embodiment, the same adhesive is used between the attachment surface 12 and the subject's skin 18 as used between the mounting surface 14 and the adhesive ring 4. Also in a preferred embodiment, the surface area of the interface between the attachment surface 12 and the subject's skin 18 is greater than the surface area of the interface between the adhesion surface 5 and the mounting surface 14. Thus, although the same adhesive is preferably used in both locations, the difference in surface area allows for greater adhesive force between the attachment surface 12 and the subject's skin 18 than between the adhesion surface 5 and the mounting surface 14. However, two different adhesives might be used with the stronger bonding adhesive between the skin and the mount.

Preferably, the mounting surface 14 is not substantially coated with adhesive. This is to avoid exposure of a sticky skin protection mount 2 to the patient's body after removal of the sensor 6 and the adhesive ring 4. For example, a premature baby may attempt to touch the mounting surface 14 after the sensor 6 is removed. However, the mounting surface 14 may be partially or completely covered with adhesive, as long as the resulting force between the adhesive ring 4 and the mounting surface 14 is less than the adhesive force between the attachment surface 12 and the subject's skin 18. While not required, a mounting surface cover (not shown) could be secured on the mounting surface 14 when the sensor 6 and adhesive ring 4 are removed, to protect the integrity of the mounting surface 14, especially if an adhesive covers the mounting surface 14 partially or completely. It will be understood that an amount of adhesive from the adhesion surface 5 may remain on the mounting surface 14 after removal of the adhesive ring 4 has been removed from the mounting surface 14. Such deposition of adhesive is expected, and does not constitute covering the mounting surface 14 with adhesive, completely or in part.

The skin protection mount 2 remains attached to the subject's skin 18 after the adhesive ring 4 has been detached from the mounting surface 14. As a result, the transcutaneous sensor 6 connected to the adhesive ring 4 can be changed out or moved as frequently as necessary without damage to the subject's skin 18 or discomfort to the subject, because the adhesive ring 4 is attaching to and detaching from the skin protection mount 2 rather than the subject's skin 18.

The thickness of the skin protection mount 2 is a tradeoff between the limitations of the transcutaneous sensor 6 and the need for patient comfort. The comfort of a patient wearing the skin protection mount 2 increases as the skin protection mount 2 grows thinner. A thinner skin protection mount 2 is more capable of flexing with the skin 18, and is less likely to cause discomfort when a subject rests or lies on it, or otherwise applies pressure to it. A countervailing consideration is the need for the skin protection mount 2 to be strong enough to withstand repeated attachment and detachment of the adhesive ring 4 without substantially tearing.

Another countervailing consideration is the operation of the transcutaneous sensor 6. In order to sense blood gas permeating through the skin 18, the transcutaneous sensor 6 typically includes an electrode (not shown) which must substantially contact the subject's skin 18 in order to perform properly. Such contact is typically through a gel or solution placed on the subject's skin 18. In known transcutaneous sensors 6, that electrode will not reliably contact the subject's skin 18 if it the transcutaneous sensor 6 is located more than substantially 8 mils from the skin. The adhesive ring 4 is typically 1-3 mils thick.

Thus, in a preferred embodiment for use with such a typical adhesive ring 4, the skin protection mount 2 is five mils thick or less, to allow the electrode from the transcutaneous sensor 6 to pass through the mount passage 16 and substantially contact the subject's skin 18. It will be noted that an increase in thickness of the adhesive ring 4 used may correspondingly decrease the thickness of the skin protection mount 2 in order to ensure that the electrode (not shown) in the transcutaneous sensor 6 substantially touches the subject's skin 18. A skin protection mount 2 thickness of five mils or less is also desirable from a patient comfort standpoint.

Preferably, the skin protection mount is substantially three mils thick. However, the skin protection mount 2 may be thinner than three mils, and made of any nontoxic thin film, so long as the skin protection mount 2 is mechanically able to withstand repeated attachment of the adhesive ring 4 to and removal of the adhesive ring 4 from the mounting surface 14 without substantially tearing.

It should also be recognized that advances in sensor technology in the future might well allow the transcutaneous sensor 6 to be placed more than 8 mils from the skin and still function effectively. Thus, within the scope of this invention, is the concept of providing a skin protection mount 2 up to substantially 25 mils thick for use with such advanced transcutaneous sensors 6. A skin protection mount 2 having a thickness of substantially 25 mils would still provide for flexibility and comfort, and would possess the same advantages and operate in the same manner as disclosed above.

When the transcutaneous sensor 6 is attached to the skin protection mount 2, the ring passage 10 and the mount passage 16 are sized and aligned such that the electrode (not shown) of the transcutaneous sensor 6 has adequate space to extend through both the ring passage 10 and the mount passage 16 and substantially touch the skin of the subject. Other than this consideration, the actual or relative size of the ring passage 10 and the mount passage 16 is not critical for obtaining the desired information. Nevertheless, the size of the mount passage 16 is constrained by the function of the skin protection mount 2. The mount passage 16 preferably encompasses a smaller area than the ring passage 10, to minimize the possibility of the adhesive ring 4 being misplaced on the skin protection mount 2 in such a way as to contact the subject's skin 18 through the mount passage 16. If the mount passage 16 is too large, then the adhesive ring 4 will simply pass through the mount passage 16 and attach directly to the skin of the subject; such attachment is what the skin protection mount 2 is intended to minimize. If the mount passage 16 is too small, the electrode in the transcutaneous sensor 6 will not be able to extend through and substantially touch the skin of the subject. Any size and shape of mount passage 16 that allows the electrode in the transcutaneous sensor 6 to extend through and substantially touch the skin of the subject, while minimizing contact between the adhesive ring 4 and the skin of the subject, is preferably used.

Additionally, the preferred size of the mount passage 16 will depend on the model of transcutaneous sensor 6 used, particularly the size of electrode utilized by the transcutaneous sensor 6. In a preferred embodiment, the skin protection mount 2 is substantially circular with a diameter of substantially 32 millimeters, and the mount passage 16 is substantially circular with a diameter of substantially 11 millimeters.

In a preferred embodiment, the surface area of the mounting surface 14 is larger than the surface area of the adhesion surface 5 of the adhesive ring 4 in order to minimize or prevent contact between the adhesive ring 4 and the subject's skin 18. FIG. 1 shows the skin protection mount 2 substantially larger than the adhesive ring 4. The skin protection mount 2 is also shaped to minimize or prevent contact between the adhesive ring 4 and the subject's skin 18. In this way, different sizes and shapes of skin protection mount 2 are contemplated for use in conjunction with different sizes and shapes of adhesive ring 4.

The majority of adhesive rings 4 in the market are substantially circular, and the majority of transcutaneous sensors 6 are substantially circular as viewed from the top. Thus, in a preferred embodiment, the skin protection mount 2 takes the form of a substantially circular disk, with a diameter larger than that of the adhesive ring 4, where the mount passage 16 is located at substantially the center of the skin protection mount 2. As seen in FIG. 4, the adhesive ring 4 is preferably attached to the skin protection mount 2 such that the two are substantially centered, allowing for simple alignment of the two. As a result, the ring passage 10 and the mount passage 16 are substantially aligned, thereby substantially preventing the adhesive ring 4 from contacting the subject's skin 18.

In an alternate embodiment, the surface area of the mounting surface 14 is substantially the same as the surface area of the adhesion surface 5 of the adhesive ring 4, and the skin protection mount 2 has a shape adapted to substantially match the shape of the adhesive ring 4 in order to minimize contact between the adhesive ring 4 and the subject's skin 18. More care must be taken with the application of the adhesive ring 4 in this alternate embodiment, as misalignment will typically result in greater contact between the adhesive ring 4 and the subject's skin 18 than in the preferred embodiment.

A preferred skin protection mount for sensor application and many of its attendant advantages have thus been disclosed. It will be apparent, however, that various changes may be made in the materials and components without departing from the spirit and scope of the invention, the materials and components hereinbefore described being merely preferred or exemplary embodiments thereof. For example, the sensor 6 and the adhesive ring 4 might be constructed as a single unit, wherein the adhesive ring 4 may be reused for multiple applications of the sensor 6. As another example, a ring cap may be provided for the adhesive ring 4 to protect the sensor and ring integrity before or after the adhesive ring 4 is attached to the skin protection mount 2. Therefore, the invention is not to be restricted or limited except in accordance with the following claims and their legal equivalents.

Stenzler, Alex

Patent Priority Assignee Title
10039881, Dec 31 2002 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
10178954, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
10201301, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
10231654, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
10349874, Sep 29 2009 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
10429250, Aug 31 2009 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
10478108, Apr 19 2007 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
10653317, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
10667700, Jul 06 2006 LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER Device and method for screening congenital heart disease
10750952, Dec 31 2002 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
10952611, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
10952652, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11045147, Aug 31 2009 Abbott Diabetes Care Inc. Analyte signal processing device and methods
11103165, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11150145, Aug 31 2009 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
11272867, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11363975, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11399748, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11471075, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11538580, Nov 04 2005 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
11612363, Sep 17 2012 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
11635332, Aug 31 2009 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
11696684, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
11793936, May 29 2009 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
11805970, Mar 09 2005 BRAEMAR MANUFACTURING, LLC Three-dimensional adhesive device having a microelectronic system embedded therein
11872370, May 29 2009 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
11911151, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
6564079, Jul 27 2000 NERVONIX, INC Electrode array and skin attachment system for noninvasive nerve location and imaging device
6609018, Jul 27 2000 NERVONIX, INC Electrode array and sensor attachment system for noninvasive nerve location and imaging device
7620438, Mar 31 2006 ABBOTT DIABETES CARE, INC Method and system for powering an electronic device
7766829, Nov 04 2005 ABBOTT DIABETES CARE, INC Method and system for providing basal profile modification in analyte monitoring and management systems
7811231, Dec 31 2002 Abbott Diabetes Care Inc Continuous glucose monitoring system and methods of use
7860544, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
7869853, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
7885699, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
7920907, Jun 07 2006 ABBOTT DIABETES CARE, INC Analyte monitoring system and method
7928850, May 08 2007 ABBOTT DIABETES CARE, INC Analyte monitoring system and methods
7976778, Apr 02 2001 Abbott Diabetes Care Inc Blood glucose tracking apparatus
8066639, Jun 10 2003 Abbott Diabetes Care Inc Glucose measuring device for use in personal area network
8103456, Jan 29 2009 ABBOTT DIABETES CARE, INC Method and device for early signal attenuation detection using blood glucose measurements
8112240, Apr 29 2005 Abbott Diabetes Care Inc Method and apparatus for providing leak detection in data monitoring and management systems
8123686, Mar 01 2007 ABBOTT DIABETES CARE, INC Method and apparatus for providing rolling data in communication systems
8149117, May 08 2007 Abbott Diabetes Care Inc Analyte monitoring system and methods
8162829, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8162830, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8175673, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8177716, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8187183, Dec 31 2002 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
8224413, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8226555, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8226557, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8226558, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8226891, Mar 31 2006 ABBOTT DIABETES CARE, INC Analyte monitoring devices and methods therefor
8231532, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8235896, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8236242, Apr 02 2001 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
8255031, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8260392, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8265726, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8268243, Apr 02 2001 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
8273022, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8275439, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8287454, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8306598, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8346336, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8346337, Nov 05 2007 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8353829, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8357091, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8362904, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
8366614, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8369924, Dec 27 2006 LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER ECG leads system for newborn ECG screening
8372005, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8380273, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8391945, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8409131, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8456301, May 08 2007 ABBOTT DIABETES CARE, INC Analyte monitoring system and methods
8461985, May 08 2007 ABBOTT DIABETES CARE, INC Analyte monitoring system and methods
8465425, Nov 01 2005 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8473021, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8473220, Jan 29 2009 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
8480580, Apr 30 1998 ABBOTT DIABETES CARE, INC Analyte monitoring device and methods of use
8512239, Jun 10 2003 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
8585591, Nov 04 2005 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
8593109, Mar 31 2006 Abbott Diabetes Care Inc. Method and system for powering an electronic device
8593287, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
8597189, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8597575, Mar 31 2006 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
8612159, Apr 30 1998 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8617071, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8622903, Dec 31 2002 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
8622906, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8641619, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8647269, Jun 10 2003 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
8649841, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8652043, Jan 02 2001 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8660627, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8660630, Dec 27 2006 LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER ECG leads system for newborn ECG screening
8665091, May 08 2007 Abbott Diabetes Care Inc.; Abbott Diabetes Care Inc Method and device for determining elapsed sensor life
8666469, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8668645, Jan 02 2001 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8670815, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8672844, Apr 30 1998 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8676513, Jan 29 2009 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
8688188, Nov 01 2005 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8732188, Feb 18 2007 ABBOTT DIABETES CARE, INC Method and system for providing contextual based medication dosage determination
8734346, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8734348, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8738109, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8744545, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8765059, Apr 02 2001 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
8771183, Dec 31 2002 Abbott Diabetes Care Inc Method and system for providing data communication in continuous glucose monitoring and management system
8774887, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8840553, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8880137, Apr 30 1998 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8892196, Jul 06 2006 Los Angeles Biomedial Research Institute at Harbor-UCLA Medical Center Device and method for screening congenital heart disease
8915850, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8920319, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8930203, Feb 18 2007 Abbott Diabetes Care Inc Multi-function analyte test device and methods therefor
8933664, Mar 31 2006 Abbott Diabetes Care Inc. Method and system for powering an electronic device
8974386, Apr 30 1998 ABBOTT DIABETES CARE, INC Analyte monitoring device and methods of use
8993331, Aug 31 2009 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
9000929, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9011331, Apr 30 1998 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
9011332, Jan 02 2001 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9014773, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9020573, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9035767, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9039975, Mar 31 2006 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
9042953, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9066694, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9066695, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9066697, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9066709, Jan 29 2009 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
9072477, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9078607, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9095290, Mar 01 2007 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
9177456, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9179874, Mar 02 2009 Covidien LP Optical-based physiological sensor assembly with disposable barrier layer
9226701, Apr 28 2009 Abbott Diabetes Care Inc Error detection in critical repeating data in a wireless sensor system
9314195, Aug 31 2009 Abbott Diabetes Care Inc Analyte signal processing device and methods
9314198, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9320461, Sep 29 2009 Abbott Diabetes Care Inc Method and apparatus for providing notification function in analyte monitoring systems
9323898, Nov 04 2005 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
9326714, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9326716, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9380971, Mar 31 2006 Abbott Diabetes Care Inc. Method and system for powering an electronic device
9477811, Apr 02 2001 Abbott Diabetes Care Inc Blood glucose tracking apparatus and methods
9498159, Jan 02 2001 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9574914, May 08 2007 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
9610034, Jan 02 2001 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9625413, Mar 31 2006 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
9649057, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9669162, Nov 04 2005 ABBOTT DIABETES CARE, INC Method and system for providing basal profile modification in analyte monitoring and management systems
9724043, Feb 15 2013 TERAS, INC Solid state diode applicator disc
9730584, Jun 10 2003 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
9743863, Mar 31 2006 Abbott Diabetes Care Inc. Method and system for powering an electronic device
9750439, Sep 29 2009 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
9801545, Mar 01 2007 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
9949678, May 08 2007 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
9962091, Dec 31 2002 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
9968302, Aug 31 2009 Abbott Diabetes Care Inc. Analyte signal processing device and methods
9968306, Sep 17 2012 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
9980669, Nov 07 2011 Abbott Diabetes Care Inc Analyte monitoring device and methods
D519210, Jul 14 2004 Electrode with disposable skin-interfaceable housing
Patent Priority Assignee Title
4051842, Sep 15 1975 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
4653501, Apr 17 1986 NDM ACQUISITION CORP Medical electrode with reusable conductor
4773424, Oct 02 1985 Fukuda Denshi Co., Ltd. Electrocardiographic electrode
4945911, Jan 22 1988 Medical electrode
4947853, May 02 1986 HON GROUP, THE Sensor support base and method of application
5848966, Mar 04 1997 Graphic Controls Corporation Medical device easily removed from skin and a method of removal therefrom
6023631, Dec 17 1996 Conmed Corporation Biomedical electrode having a disposable electrode and a reusable leadwire adapter that interfaces with a standard leadwire connector
/////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Jan 04 2000SensorMedics Corporation(assignment on the face of the patent)
Jan 04 2000STENZLER, ALEXSensorMedics CorporationASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0104860768 pdf
Apr 16 2018SensorMedics CorporationWILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENTSECOND LIEN SECURITY AGREEMENT0457820851 pdf
Apr 16 2018SensorMedics CorporationBANK OF AMERICA, N A , AS COLLATERAL AGENTFIRST LIEN SECURITY AGREEMENT0459680865 pdf
May 03 2019SensorMedics CorporationWILMINGTON TRUST, NATIONAL ASSOCIATIONSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0491260905 pdf
Date Maintenance Fee Events
Mar 24 2005M1551: Payment of Maintenance Fee, 4th Year, Large Entity.
Sep 04 2008ASPN: Payor Number Assigned.
Mar 25 2009M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Feb 27 2013M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Sep 25 20044 years fee payment window open
Mar 25 20056 months grace period start (w surcharge)
Sep 25 2005patent expiry (for year 4)
Sep 25 20072 years to revive unintentionally abandoned end. (for year 4)
Sep 25 20088 years fee payment window open
Mar 25 20096 months grace period start (w surcharge)
Sep 25 2009patent expiry (for year 8)
Sep 25 20112 years to revive unintentionally abandoned end. (for year 8)
Sep 25 201212 years fee payment window open
Mar 25 20136 months grace period start (w surcharge)
Sep 25 2013patent expiry (for year 12)
Sep 25 20152 years to revive unintentionally abandoned end. (for year 12)